JPMorgan Chase & Co. Cuts Stock Position in Bioventus Inc. $BVS

Key Points

• JPMorgan Chase cut its Bioventus position by 52.9% in Q3, selling 128,933 shares and leaving 114,777 shares (about 0.14% of the company) valued at $768,000.
• Director Michelle Mcmurry‑Heath sold 12,000 shares (a 21.05% reduction in her stake); ownership is concentrated with insiders at 33% and institutional investors holding roughly 62.94%.
• Bioventus trades near $9.06 with a market cap of about $753M, recently beat EPS estimates and set FY2026 guidance of $0.73–$0.77, while analysts have a consensus Buy rating and an average target of $14.00.

JPMorgan Chase & Co. lowered its position in Bioventus Inc. (NASDAQ:BVS - Free Report) by 52.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 114,777 shares of the company's stock after selling 128,933 shares during the period. JPMorgan Chase & Co. owned approximately 0.14% of Bioventus worth $768,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Covestor Ltd grew its position in Bioventus by 28.0% during the 3rd quarter. Covestor Ltd now owns 9,951 shares of the company's stock worth $67,000 after purchasing an additional 2,176 shares during the last quarter. HB Wealth Management LLC purchased a new stake in Bioventus during the 3rd quarter worth approximately $72,000. Prelude Capital Management LLC purchased a new stake in Bioventus during the 3rd quarter worth approximately $74,000. Olympiad Research LP purchased a new stake in Bioventus during the 3rd quarter worth approximately $74,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in Bioventus during the 3rd quarter worth approximately $78,000. Hedge funds and other institutional investors own 62.94% of the company's stock.

Bioventus Stock Performance

Shares of NASDAQ BVS opened at $9.06 on Friday. The company has a current ratio of 1.70, a quick ratio of 1.19 and a debt-to-equity ratio of 1.22. Bioventus Inc. has a 12 month low of $5.81 and a 12 month high of $9.53. The company has a 50 day simple moving average of $8.71 and a two-hundred day simple moving average of $7.81. The stock has a market cap of $753.34 million, a price-to-earnings ratio of 27.45 and a beta of 0.70.

Bioventus (NASDAQ:BVS - Get Free Report) last announced its quarterly earnings data on Thursday, March 5th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.22 by $0.02. Bioventus had a net margin of 4.00% and a return on equity of 28.88%. The business had revenue of $157.90 million during the quarter. Bioventus has set its FY 2026 guidance at 0.730-0.770 EPS.

Insider Buying and Selling

In related news, Director Michelle Mcmurry-Heath sold 12,000 shares of the business's stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total value of $105,480.00. Following the completion of the transaction, the director directly owned 44,997 shares in the company, valued at $395,523.63. The trade was a 21.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 33.00% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on BVS. Weiss Ratings reissued a "hold (c-)" rating on shares of Bioventus in a research report on Monday, December 29th. CJS Securities began coverage on shares of Bioventus in a research report on Friday, March 27th. They set a "market outperform" rating and a $14.00 target price on the stock. Craig Hallum boosted their target price on shares of Bioventus from $15.00 to $16.00 and gave the stock a "buy" rating in a research report on Friday, March 6th. Cantor Fitzgerald raised shares of Bioventus to a "strong-buy" rating in a research report on Wednesday, March 4th. Finally, Barrington Research boosted their target price on shares of Bioventus from $13.00 to $14.00 and gave the stock an "outperform" rating in a research report on Friday, March 6th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, Bioventus currently has a consensus rating of "Buy" and an average price target of $14.00.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.